TY - JOUR
AU - Ikeda, Mie
AU - Kaneko, Megumi
AU - Tachibana, Shin-Ichiro
AU - Balikagala, Betty
AU - Sakurai-Yatsushiro, Miki
AU - Yatsushiro, Shouki
AU - Takahashi, Nobuyuki
AU - Yamauchi, Masato
AU - Sekihara, Makoto
AU - Hashimoto, Muneaki
AU - Katuro, Osbert
AU - Olia, Alex
AU - Obwoya, Paul
AU - Auma, Mary
AU - Anywar, Denis
AU - Odongo-Aginya, Emmanuel
AU - Okello-Onen, Joseph
AU - Hirai, Makoto
AU - Ohashi, Jun
AU - Palacpac, Nirianne M.Q.
AU - Kataoka, Masatoshi
AU - Tsuboi, Takafumi
AU - Kimura, Eisaku
AU - Horii, Toshihiro
AU - Mita, Toshihiro
T1 - Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016
T2 - Emerging Infectious Disease journal
PY - 2018
VL - 24
IS - 4
SP - 718
SN - 1080-6059
AB - Because ≈90% of malaria cases occur in Africa, emergence of artemisinin-resistant Plasmodium falciparum in Africa poses a serious public health threat. To assess emergence of artemisinin-resistant parasites in Uganda during 2014–2016, we used the recently developed ex vivo ring-stage survival assay, which estimates ring-stage–specific P. falciparum susceptibility to artemisinin. We conducted 4 cross-sectional surveys to assess artemisinin sensitivity in Gulu, Uganda. Among 194 isolates, survival rates (ratio of viable drug-exposed parasites to drug-nonexposed controls) were high (>10%) for 4 isolates. Similar rates have been closely associated with delayed parasite clearance after drug treatment and are considered to be a proxy for the artemisinin-resistant phenotype. Of these, the PfKelch13 mutation was observed in only 1 isolate, A675V. Population genetics analysis suggested that these possibly artemisinin-resistant isolates originated in Africa. Large-scale surveillance of possibly artemisinin-resistant parasites in Africa would provide useful information about treatment outcomes and help regional malaria control.
KW - Artemisinin
KW - drug resistance
KW - Plasmodium falciparum
KW - Uganda
KW - parasites
KW - malaria
KW - antimicrobial resistance
DO - 10.3201/eid2404.170141
UR - https://wwwnc.cdc.gov/eid/article/24/4/17-0141_article
ER - End of Reference